hhen ammonium sulfate-iron oxide is treated below 573 K, ammonium sulfate can spontaneously desperse on the surface of iron oxide. Simultaneously ammonium sulfate decomposes to some extent. During or after the dispers...hhen ammonium sulfate-iron oxide is treated below 573 K, ammonium sulfate can spontaneously desperse on the surface of iron oxide. Simultaneously ammonium sulfate decomposes to some extent. During or after the dispersion, sulfate ion can interact with Fe atom on the surface of iron oxide to form a sort of surface sulfato complex of Fe and thus is transformed from the isolated into the bidentately bound form. Above 573 K the sulfato complex of Fe will gradually decompose with a further increase in temperature.展开更多
The development and influencing factors of compliance behavior of investigators in clinical trials were explored. According to literature review, a hypothetical model of development of compliance behavior of investiga...The development and influencing factors of compliance behavior of investigators in clinical trials were explored. According to literature review, a hypothetical model of development of compliance behavior of investigators in clinical trials was established, and the influencing factors of compliance behavior of investigators and their interrelationships were studied based on questionnaire survey of five hundred investigators sampled randomly from one hundred clinical trial institutions in China. Cron- bach＇s alpha coefficient and structural equation modeling were adopted to empirically analyze the re- suits. Six variables in the hypothetical model were included： compliance behavior of investigators, credibility of clinical trial, capability of government regulation, quality control of sponsor, quality con- trol of clinical institution and compliance intention of investigators. Empirical analysis showed that the compliance behavior of investigators in clinical trial was directly affected by compliance intention of investigators, quality control of sponsor and quality control of clinical institution. In addition, credibility of clinical trial and capability of government regulation indirectly affected the compliance behavior of investigators in clinical trial through influencing the compliance intention of investigators, quality con- trol of sponsor and quality control of clinical institution. Quality control of sponsor was affected by credibility of clinical trial and capability of government regulation while quality control of clinical in- stitutinn wan only influenced by capability of government regulation.展开更多
文摘hhen ammonium sulfate-iron oxide is treated below 573 K, ammonium sulfate can spontaneously desperse on the surface of iron oxide. Simultaneously ammonium sulfate decomposes to some extent. During or after the dispersion, sulfate ion can interact with Fe atom on the surface of iron oxide to form a sort of surface sulfato complex of Fe and thus is transformed from the isolated into the bidentately bound form. Above 573 K the sulfato complex of Fe will gradually decompose with a further increase in temperature.
文摘The development and influencing factors of compliance behavior of investigators in clinical trials were explored. According to literature review, a hypothetical model of development of compliance behavior of investigators in clinical trials was established, and the influencing factors of compliance behavior of investigators and their interrelationships were studied based on questionnaire survey of five hundred investigators sampled randomly from one hundred clinical trial institutions in China. Cron- bach＇s alpha coefficient and structural equation modeling were adopted to empirically analyze the re- suits. Six variables in the hypothetical model were included： compliance behavior of investigators, credibility of clinical trial, capability of government regulation, quality control of sponsor, quality con- trol of clinical institution and compliance intention of investigators. Empirical analysis showed that the compliance behavior of investigators in clinical trial was directly affected by compliance intention of investigators, quality control of sponsor and quality control of clinical institution. In addition, credibility of clinical trial and capability of government regulation indirectly affected the compliance behavior of investigators in clinical trial through influencing the compliance intention of investigators, quality con- trol of sponsor and quality control of clinical institution. Quality control of sponsor was affected by credibility of clinical trial and capability of government regulation while quality control of clinical in- stitutinn wan only influenced by capability of government regulation.
